Crossover Trial of AD109 in Obstructive Sleep Apnea

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 27, 2020

Primary Completion Date

May 28, 2021

Study Completion Date

May 28, 2021

Conditions
Obstructive Sleep Apnea
Interventions
DRUG

AD109

Oral administration before bed

DRUG

Atomoxetine

Oral administration before bed

DRUG

R-oxybutynin

Oral administration before bed

DRUG

Placebo

Oral administration before bed

DIAGNOSTIC_TEST

Digit System Substitution Test

a neuropsychological test sensitive to brain damage, dementia, age and depression where numbers are assigned symbols. Under each digit the subject should write down the corresponding symbol as fast as possible. The number of correct symbols within the allowed time is measured.

Trial Locations (7)

30501

The Neurological Center of North Georgia, Gainesville

33186

Clinical Trials of Florida, Miami

33511

Teradan Clinical Trials, Brandon

45212

CTI Clinical Research Center, Cincinnati

72211

Preferred Research Partners, Inc., Little Rock

91767

Empire Clinical Research, Pomona

06511

Yale University, New Haven

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Apnimed

INDUSTRY

NCT04580394 - Crossover Trial of AD109 in Obstructive Sleep Apnea | Biotech Hunter | Biotech Hunter